THE DRUG SAFETY AND EFFECTIVENESS CROSS-DISCIPLINARY TRAINING (DSECT) PROGRAM

Main Article Content

Lisa Dolovich
Lehana Thabane
Mitch Levine
Anne Holbrook
Parminder Raina
Ron Goeree
Kalpana Nair
Kennedy Riemersma
Joanne Kehoe

Keywords

Medication safety, training, cross-disciplinary, program overview, Canada

Abstract

Clinical therapeutics are a cornerstone of treatment for most medical conditions. Pharmacotherapy research is a substantial worldwide enterprise. There are too few researchers who are flexible enough to understand how molecules move from bench to bedside and how their own work transcends conventional boundaries. The Drug Safety and Effectiveness Cross-Disciplinary (DSECT) Training Program has been designed to provide a training environment for future scientists in Canada to generate new knowledge that is focused on integrative thinking about the discovery and use of effective and safe medications. This one-year program fosters cross-domain learning and collaboration using a multi-pronged approach to encourage development of both content-focused and research methods knowledge related to drug safety and effectiveness, as well as practical skill and capacity building. The curriculum consists of: an annual symposium, development of an individualized learning plan, one-to-one mentorship, a series of on-line sessions on integrative concepts in drug safety and effectiveness, on-line self-study modules and discussion sessions, a series of practical research skill-building sessions, practicum/exposure opportunities, a seminar series, an Objective Structured Knowledge Translation Experience (OSKTE) and a Book Club. This innovative curriculum is poised to broaden and strengthen the competency and culture of drug safety and effectiveness research while capitalizing on the benefits derived from knowledge pursuit that crosses multiple domains of the scientific academy.

Abstract 200 | PDF Downloads 65

References

1. Li S, Tomalin A. Patentees research and development expenditure in Canada. J Pharm Pharmaceut Sci 2002;5:5-11.
2. Biomedical graduate education a prescription for the 21st century. Canadian Society of Pharmacology and Therapeutics [1996 Available from: URL:http://www.pharmacologycanada.org/docu ments/biomedgr.html
3. Fox G, Otten N. Medicines that Work for Canadians: Business Plan for a Drug Effectiveness and Safety Network. Health Canada 2007:[1-87] Available from: URL:http://www.hc-sc.gc.ca/hcssss/ pubs/pharma/2007-med-work_eff/drug-medeng. php#4
4. Choudhry NK, Patrick AR, Glynn RJ, Avorn J. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol 2011;57(7): 784-91.
5. Franco OH, Peeters A, Looman CWN, Bonneux L. Cost effectiveness of statins in coronary heart disease. Journal of Epidemiology and Community Health 2005;59(11):927-33.
6. Hutz MH, Fiegenbaun M. Impact of genetic polymorphisms on the efficacy of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2008;8(3):161-70.
7. Ontario Ministry of Health and Long Term Care. 2004-2005 Report card for Ontario Drug Benefit Program. 2005.
8. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascularevents in men and women with elevated C-reactive protein. New England Journal of Medicine 2008; 359(21): 2195-207.
9. Schmitz G, Schmitz-Madry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Current Opinion in Lipidology 2007;18(2):164-73.
10. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004; 291:2243-52.
11. Holbrook A, Wright M, Sung M, Ribic C, Baker S. Statin-associated rhabdomyolysis: Is there a dose-response relationship? Canadian Journal of Cardiology 2003;27(2):146-51.
12. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: Results from the justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121(9):1069-77.
13. Farahani P, Levine M. Pharmacavigilance in a genomic era. Pharmacogenomics Journal 2006; 6(3):158-61.
14. Feinberg AP. Epigenetics at the epicenter of modern medicine. Journal of the American Medical Association 2008;299(11):1345-50.
15. Esteller M. Epigenetics in cancer. New England Journal of Medicine 2008;358(11):1148-59.
16. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised trials. Lancet 2008;370(9605):2118-25.
17. Harden RM, Stevenson M, Downie WW, Wilson GM. Assessment of clinical competence using objective structured examination. British Medical Journal 1975;1(5955):447-51.
18. Rushforth H. Objective structured clinical examination (OSCE): Review of literature and implications for nursing education. Nurse Education Today 2007;27(5):481-90.
19. McAleer S, Walker R. Objective structured clinical examination (OSCE). Occas Pap R Coll Gen Pract 1990;46:39-42.

Most read articles by the same author(s)

1 2 > >>